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Abstract: 
A step-economical synthesis of clinprost is reported that concludes with 3 different transition 
metal-catalyzed reactions: Pd-catalyzed decarboxylation with allylic rearrangement, Rh-
catalyzed diene-ene [2+2+1] reaction, and Ru-catalyzed cross-metathesis reaction. The 
complexity bestowed to the molecule from these reactions converts a readily accessible ester to 
clinprost without using protecting groups in only 9 total steps. 
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Article: 
The number of steps of a synthesis can significantly impact its cost, yield, waste, and required 
time. For these reasons, efforts are being made to design and develop more step-economical 
syntheses.(1) In order to shorten the number of steps of a synthesis there is a need to increase 
target-relevant molecular complexity more quickly. This is often accomplished via the design 
and development of new reactions. Transition metals play a unique role in the development of 
new reactions since they often significantly increase the structural complexity of the molecule 
while exhibiting high chemoselectivity which obviates the requirement of protecting groups. 
These characteristics imbue step-economical features to the overall process to enable a more 
practical synthesis. 
Prostacyclin (1) is a potent, endogenous vasodilator and inhibitor of platelet aggregation that was 
first structurally characterized in 1976 (Figure 1).(2) Although prostacyclin is a gold standard for 
vasodilation due to its potency, it has a half-life of approximately 3 min in vivo due to the 
presence of a vinyl ether and carboxylic acid. Carbacyclin (2) was designed to be a more stable 
analogue and related structures, including Iloprost, Beraprost, and Treprostinil, have been 
developed into pharmaceutical drugs for indications related to vasodilation including the 
treatment of patients with pulmonary arterial hypertension.(3) Clinprost (5), the methyl ester of 
isocarbacyclin (4), was similarly designed; however, clinprost was also found to be a potent 
neuroprotective compound in animal studies(4) and efficiently crossed the blood–brain 
barrier.(5) Clinprost, isocarbacyclin, and their analogues have been synthesized by many 
groups,(6) usually building off of the seminal work of the prostaglandin syntheses.(7) Although 
the numerous reported syntheses of clinprost are diverse in their approaches,(8) most are more 
than 20 steps from commercially available materials with the shortest reported syntheses 
requiring 15 total steps.(6m, 6p, 6r, 6s) With the research described herein, we disclose the 
synthesis of clinprost (5), where three late-stage steps use fundamentally different transition 
metal-catalyzed reactions to assemble the molecule. The chemoselectivity and rapid introduction 
of complexity resulted in an enantioselective synthesis of clinprost that is 9 total steps from 
commercially available materials, which makes this synthesis at least 6 fewer steps compared to 
other reports. 
 
Figure 1. Structure of prostacyclin, clinprost, and analogues. 
The approach we took for synthesizing clinprost (5) takes advantage of attaching the allylic 
alcohol side chain, or ω-side chain, at a late stage using a cross-metathesis reaction (Scheme 1). 
This cross-metathesis approach has been previously reported; however, in our synthesis, the 
bicyclic core and upper side chain map directly onto the target and require no further 
modifications. Due to the broad range of available primary alkenes, this design will enable facile 
access to analogues that explore the activity of compounds with diverse ω-side chains in future 
studies. To rapidly assemble the bicyclo[3.3.0]octene core with an appended alkene, a diene-ene 
[2+2+1] reaction(9) was envisioned with in situ reduction of the resultant ketone from the 
convex face of the bicycle.(9b) The requisite tetraene (7) for this reaction, although simplistic in 
appearance, is complicated by the methylene adjacent to the two conjugated dienes. After 
multiple routes to synthesize tetraene 7 were unsuccessful, a palladium(0)-catalyzed 
decarboxylation with concomitant allylic transposition was designed. If successful, this excision 
of carbon dioxide would be a rare report of a metal-catalyzed decarboxylation of either a bis-
allylic ester or of an ester without an anion-stabilizing group attached. Importantly, this 
decarboxylation with isomerization of the diene provides for a major simplification of the 
starting material to ester 8. We envisioned that dienoate 8 could be easily accessed via 
esterification using divinyl carbinol (11) and a subsequent aldol condensation with acrolein (9). 
 
Scheme 1. Retrosynthesis of Clinprost 
With ester 15 in hand, conditions for the decarboxylation were examined (Table 1). We 
envisioned that this reaction might be successful since metal-catalyzed rearrangements(10) and 
substitutions(11) of bis-allylic systems were known. After moderate experimentation, it was 
found that 1,4-pentadienyl ester 15 quickly formed 1,3-pentadienyl ester 16 (entry 1). If the 
reaction is allowed to continue, this ester apparently reenters the catalytic cycle to yield desired 
bis-diene 17 (entry 2). Although decarboxylative allylations are known for allylic esters where 
the α position of the ester has an anion-stabilizing group such as a carbonyl, there is little 
precedence for decarboxylations where a non-stabilized Pd–C bond is formed.(12) In fact, it is 
stated in the conclusion of a recent review that, “A major limitation of current methods is that 
anion-stabilizing groups are often required...” and “...decarboxylative allylations of simple alkyl 
or alkenyl nucleophiles would significantly expand the scope...”.(12b) The limitation of 
requiring an anion-stabilizing group has clearly been broken, at least with the system reported 
herein, since vinyl anions are not typically considered anion-stabilizing. What is also curious 
about this novel decarboxylation is that the initial E/Z ratio of the starting material has a minimal 
effect on the final ratio in the product (compare entries 3 and 4). Preliminary results indicate that 
the E/Z ratio of 15 is correlated to ester 16, but during the decarboxylation this stereochemical 
information is scrambled. 
 
entry 15 (E/Z) time product % yield 
1 1:1 1 h 16 quantb 
2 1:1 24 h 17(1:1E/Z) 73% 
3 10:1 24 h 17(1.3:1E/Z) 62% 
4 3:7 24 h 17(0.9:1E/Z) 69% 
aConditions: 15 (1 equiv) was dissolved in dichloromethane (0.07 M), Pd(PPh3)4 (10 mol %) 
was added and the reaction was stirred at rt for the indicated time. 
bAs determined by crude 1H NMR. 
Interestingly, this decarboxylation with allylic transposition proceeds at room temperature even 
though many decarboxylations, such as those forming acetylides,(13) require much higher 
temperatures. The gentle conditions described, however, do not adequately do justice to the 
specific nature of this system. For example, similar compounds that possess the 1,4-pentadienyl 
group but lack the 1,3-dienoate will isomerize to the 1,3-pentadienyl ester but do not 
decarboxylate. Furthermore, it was determined that trace amounts of water were highly 
beneficial for the decarboxylation after observing that older bottles of catalyst were more active 
(see Supporting Information for more details). The optimization and further exploration of this 
potential Black Swan Event,(14, 15) including exploring E/Z selectivities, will be reported at a 
later date. 
 
Using tetraene 17, conditions for the diene-ene [2+2+1] reaction were explored using 
rhodium(I)-catalysts (Scheme 3). Gratifyingly, cyclopentanone 20 was synthesized as a single 
diastereomer, but only one stereoisomer of tetraene 17 was reactive and E-17 was recovered.(16) 
It was previously reported that a cis-diene isomerized to a trans-diene when tethered to an alkene 
in the presence of a rhodium(I) catalyst,(9b) however, isomerization did not occur with E-17. 
The current system is more hindered and presumably not sufficiently reactive. Similar to these 
prior studies, cyclopentanone 20 was sensitive and isomerized to the more stable enone (21). The 
yields for forming bicycle 20 were moderate to low, but after screening other catalysts, additives, 
and solvents, it was unfortunately determined that more active catalysts for the [2+2+1] reaction 
tended to isomerize ketone 20 into enone 21 to a greater degree. Ketone 20 was 
diastereoselectively reduced from the convex face to yield bicyclic alcohol 22 and enone 21 
could be removed since it was less reactive. In order to streamline the synthesis while avoiding 
isomerization issues, ketone 20 was reduced in situ with sodium borohydride to directly isolate 
alcohol 22 from the reaction. Although the efficiency to transform tetraene 17 into alcohol 22 is 
low, this reaction assembles both rings of the target, forms three C–C bonds, and 
diastereoselectively sets four of the five chiral centers in clinprost, and is the first [2+2+1] 
cyclocarbonylation reaction of tethered dienes. 
 
Scheme 3. Synthesis of the Bicyclic Core 
To complete the synthesis of clinprost, a cross-metathesis reaction was utilized to attach the 
alkenyl-side chain (Scheme 4), which was synthesized using enzymatic resolution of racemic 1-
octen-3-ol (see Supporting Information for more details including reactions with the analogous 
silyl ether).(17) The cross-metathesis reaction worked similarly to a prior report,(6a, 18) but it is 
worth noting that our route requires fewer steps to both metathesis partners. Another advantage 
of this synthesis is that the completion only requires methanolysis at this stage to yield clinprost 
(5), and its diastereomer (dia-5) in a 1:1 ratio(19) as compared to 4 steps required for the prior 
metathesis route.(6a) Thus, the enantioselective synthesis of clinprost was accomplished in only 
9 total steps from commercially available materials without the use of protecting groups.(20) 
 
Scheme 4. Endgame of the Clinprost Synthesis 
In conclusion, we report a synthesis of clinprost (5) that uses three transition metals, Pd0, RhI, 
and RuII, to catalyze reactions that rapidly form the requisite molecular complexity of the 
molecule. The palladium(0)-catalyzed step is unprecedented for either an allylic decarboxylation 
without an anion-stabilizing group or a bis-allylic ester. The rhodium(I)-catalyzed step is the first 
diene-ene [2+2+1] reaction of tethered dienes and is coupled with an in situ reduction to 
assemble the bicyclic core and diastereoselectively set four of the five chiral centers in clinprost. 
The ruthenium(II)-catalyzed step attaches the enantiomerically enriched side chain to assemble 
the carbon skeleton of clinprost. The chemoselectivity of the transition metal-catalyzed reactions 
of this route precluded the use of protecting groups which enabled the synthesis to be at least 6 
steps fewer than prior syntheses of clinprost or isocarbacyclin. The cross-metathesis reaction is 
currently being used to attach other side chains in order to learn more about the neuroprotective 
nature of clinprost. These results will be reported in the near future, along with an in-depth study 
of the novel decarboxylation reactions uncovered. 
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